We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

In the last reported quarter, REGN beat on earnings by 3.87%. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Our proven model does not ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes ...